Literature DB >> 2890807

Effect of unnatural noradrenaline precursor on sympathetic control and orthostatic hypotension in dopamine-beta-hydroxylase deficiency.

A J Man in 't Veld1, F Boomsma, A H van den Meiracker, M A Schalekamp.   

Abstract

A patient with severe orthostatic hypotension due to dopamine-beta-hydroxylase deficiency was treated with the unnatural aminoacid D,L-threo-3,4-dihydroxyphenylserine (DOPS) in the hope that it would serve as a substrate of aromatic-L-aminoacid decarboxylase to produce (-)-noradrenaline. With a dose of 500 mg twice daily by mouth, blood pressure rose gradually from 100/55 to 145/85 mm Hg, and orthostatic hypotension disappeared. After 4 months' treatment the patient is free of symptoms and able to live a normal life. DOPS switched on the production of noradrenaline and reduced the excessive production of dopamine. During treatment plasma noradrenaline rose normally after standing and after infusion of tyramine, a biogenic amine that liberates stored neurotransmitter from sympathetic nerve terminals. These data demonstrate that in congenital dopamine-beta-hydroxylase deficiency dopamine instead of noradrenaline is released as the sympathetic neurotransmitter but that the integrity of the sympathetic neuron is otherwise intact.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2890807     DOI: 10.1016/s0140-6736(87)91318-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  14 in total

Review 1.  Management of neurogenic orthostatic hypotension in patients with autonomic failure.

Authors:  Christoph Schroeder; Jens Jordan; Horacio Kaufmann
Journal:  Drugs       Date:  2013-08       Impact factor: 9.546

Review 2.  L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience.

Authors:  Christopher J Mathias
Journal:  Clin Auton Res       Date:  2008-03-27       Impact factor: 4.435

3.  Sleep patterns in congenital dopamine beta-hydroxylase deficiency.

Authors:  J H Tulen; A J Man in't Veld; K Mechelse; F Boomsma
Journal:  J Neurol       Date:  1990-04       Impact factor: 4.849

4.  Droxidopa in neurogenic orthostatic hypotension.

Authors:  Horacio Kaufmann; Lucy Norcliffe-Kaufmann; Jose-Alberto Palma
Journal:  Expert Rev Cardiovasc Ther       Date:  2015-06-19

5.  Prospects for droxidopa in neurogenic orthostatic hypotension.

Authors:  Amanda J Ross; Julian M Stewart
Journal:  Hypertension       Date:  2014-10-27       Impact factor: 10.190

6.  Neurocognitive function in dopamine-β-hydroxylase deficiency.

Authors:  Marieke Jepma; Jaap Deinum; Christopher L Asplund; Serge Arb Rombouts; Jouke T Tamsma; Nathanja Tjeerdema; Michiel M Spapé; Emily M Garland; David Robertson; Jacques Wm Lenders; Sander Nieuwenhuis
Journal:  Neuropsychopharmacology       Date:  2011-04-06       Impact factor: 7.853

7.  L-threo-dihydroxyphenylserine corrects neurochemical abnormalities in a Menkes disease mouse model.

Authors:  Anthony Donsante; Patricia Sullivan; David S Goldstein; Lauren R Brinster; Stephen G Kaler
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

Review 8.  Update on the theory and management of orthostatic intolerance and related syndromes in adolescents and children.

Authors:  Julian M Stewart
Journal:  Expert Rev Cardiovasc Ther       Date:  2012-11

9.  L-threo-3,4-dihydroxyphenylserine, a noradrenaline precursor, inhibits dopamine release and metabolism in the rat striatum in vivo.

Authors:  K Mizoguchi; M Tanaka; H Yokoo; M Yoshida; A Tsuda
Journal:  Experientia       Date:  1992-12-01

Review 10.  L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience.

Authors:  Horacio Kaufmann
Journal:  Clin Auton Res       Date:  2008-03-27       Impact factor: 4.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.